

| Author Year; Country Score Research Design Sample Size | Methods | Outcome |
|---|---|---|
| Vaidyanathan et al. 1998; UK Pre-post N=24 | <p>Population: 18 adults with tetraplegia (17 male, 1 female), 3 children with ventilator-dependent tetraplegia and 3 adult males with paraplegia. All had AD in the absence of an acute factor.</p> <p>Treatment: Administration of Terazosin with starting dose of 1 mg (adults) or 0.5 mg (children). Step-wise increments of these doses were given at 3-4 day intervals.</p> <p>Outcome Measures: drug-induced hypotension, adverse effects, AD symptoms.</p> | <ol style="list-style-type: none"> 1. The AD symptoms subsided completely with the Terazosin therapy in all the patients. 2. Adult patients required a dose between 1-10 mg and children required between 1-2 mg. 3. The side effects of postural hypotension and drowsiness were transient and mild. One tetraplegic patient developed persistent dizziness and therapy was discontinued. |
| Chancellor et al. 1994; USA Pre-post N=21 | <p>Population: 21 subjects with complete SCI; injury level C3-T5.</p> <p>Treatment: Terazosin administration.</p> <p>Outcome Measures: blood pressure and autonomic dysreflexia frequency and severity scores</p> | <ol style="list-style-type: none"> 1. Decrease in the AD severity score from baseline at one week, 1 month and 3 months. 2. Degree of muscle spasm and degree of headache did not improve. 3. Decrease in the frequency of AD at 1-week follow-up and was maintained at 1 and 3 months. 4. SBP did not statistically change after 3 months of Terazosin. |
| Swierzewski et al. 1994; USA Pre-post N=12 | <p>Population: 6 subjects with paraplegia, 6 with quadriplegia.</p> <p>Treatment: nightly Terazosin administration for 4 weeks (5 mg starting dose).</p> <p>Outcome Measures: physical examination, cystoscopy, AD symptoms.</p> | <ol style="list-style-type: none"> 1. Detrusor compliance improved in all patients during the treatment phase. 2. Change in bladder pressure and safe bladder volume were statistically and clinically significant. 3. Terazosine abolished AD in 3 patients and decreased the incidence and the severity of symptoms in 1 patient. |